BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BC Week In Review | Feb 1, 2019
Financial News

Corbus raises $35M follow-on

Inflammatory and fibrotic diseases company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) raised $35 million on Jan. 25 through the sale of 5.4 million shares at $6.50 in a follow-on underwritten by Jefferies, RBC, JMP, Oppenheimer and...
BC Week In Review | Sep 21, 2018
Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases. Jenrin will receive $250,000 upfront and is...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
BC Week In Review | Aug 3, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
BC Extra | Aug 2, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
BC Extra | Jun 6, 2018
Company News

Ex-FDA official Jenkins joins Corbus' board

John Jenkins, the longtime director of FDA's Office of New Drugs (OND), has been named a director at inflammatory and fibrotic disease company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Jenkins joined FDA in 1992 and was...
BioCentury | Feb 10, 2018
Finance

Foundation validation

The not-for-profit Cystic Fibrosis Foundation is putting its weight behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Corbus plans to use the award to validate...
BC Week In Review | Feb 2, 2018
Company News

Corbus gets $25M from CF Foundation for Ph IIb study

The not-for-profit Cystic Fibrosis Foundation (Bethesda, Md.) awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of the company's lenabasum (formerly anabasum) to treat cystic fibrosis. The...
BC Extra | Jan 30, 2018
Company News

CF Foundation grants Corbus $25M for Phase IIb study

The not-for-profit Cystic Fibrosis Foundation awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of the company's lenabasum (formerly anabasum) to treat cystic fibrosis. The award, announced...
Items per page:
1 - 10 of 29
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BC Week In Review | Feb 1, 2019
Financial News

Corbus raises $35M follow-on

Inflammatory and fibrotic diseases company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) raised $35 million on Jan. 25 through the sale of 5.4 million shares at $6.50 in a follow-on underwritten by Jefferies, RBC, JMP, Oppenheimer and...
BC Week In Review | Sep 21, 2018
Company News

Corbus gets over 600 endocannabinoid-targeting compounds from Jenrin

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) acquired exclusive, worldwide rights to over 600 endocannabinoid system-targeting compounds from Jenrin Discovery LLC (Chadds Ford, Pa.) to treat inflammatory and fibrotic diseases. Jenrin will receive $250,000 upfront and is...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
BC Week In Review | Aug 3, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
BC Extra | Aug 2, 2018
Clinical News

Celtaxsys planning Phase III program for CF candidate

Celtaxsys Inc. (Atlanta, Ga.) said it hopes to start Phase III testing in 2H19 evaluating acebilustat (CTX-4430) to treat cystic fibrosis after reporting data from the Phase II EMPIRE-CF trial of the candidate in the...
BC Extra | Jun 6, 2018
Company News

Ex-FDA official Jenkins joins Corbus' board

John Jenkins, the longtime director of FDA's Office of New Drugs (OND), has been named a director at inflammatory and fibrotic disease company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Jenkins joined FDA in 1992 and was...
BioCentury | Feb 10, 2018
Finance

Foundation validation

The not-for-profit Cystic Fibrosis Foundation is putting its weight behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Corbus plans to use the award to validate...
BC Week In Review | Feb 2, 2018
Company News

Corbus gets $25M from CF Foundation for Ph IIb study

The not-for-profit Cystic Fibrosis Foundation (Bethesda, Md.) awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of the company's lenabasum (formerly anabasum) to treat cystic fibrosis. The...
BC Extra | Jan 30, 2018
Company News

CF Foundation grants Corbus $25M for Phase IIb study

The not-for-profit Cystic Fibrosis Foundation awarded Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) up to $25 million to support a planned Phase IIb trial of the company's lenabasum (formerly anabasum) to treat cystic fibrosis. The award, announced...
Items per page:
1 - 10 of 29